WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 20, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 4, 2022 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 3, 2022-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 30, 2022 , the compensation committee of the Company’s Board of Directors approved
Mirvetuximab Plus Bevacizumab Demonstrated Meaningful Efficacy in Recurrent FRα-Positive Ovarian Cancer Across a Broad Range of FRα Expression Regardless of Prior Treatment; Data to be Highlighted in Oral Presentation Additional Clinical Benefit Outcomes from Pivotal SORAYA Study Also Reported
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 14, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, will participate in a fireside chat at the upcoming
Patient-Reported Outcomes with Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 11, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 1, 2022-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on August 31, 2022 , the compensation committee of the Company’s Board of Directors approved grants
Review of Data from First 10 Patients Demonstrates Significant Activity and Favorable Tolerability in Both De Novo BPDCN Patients and Those with a P rior or Concomitant Hematologic Malignancy (PCHM) Following Discussion with FDA, CADENZA Patients to be Segmented into De Novo and PCHM BPDCN
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 1, 2022-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on July 29, 2022 , the compensation committee of the Company’s Board of Directors approved grants
BLA for Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer Accepted by FDA with Priority Review; PDUFA Date Set for November 28, 2022 Completed enrollment in the Confirmatory MIRASOL Study Presented Additional Efficacy and Safety Data for Mirvetuximab Monotherapy at ASCO; Poster Highlighting
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 14, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 29, 2022 to discuss its